SEC22A

Across TCGA pan-cancer cohorts, SEC22A mass-spec protein is linked to patient survival in 5 of 34 cancer types, making it a survival-associated SEC22A data layer compared with 22 for mass-spec protein and 1 for mutation status.

The strongest signal is observed in head and neck squamous cell carcinoma (HNSC), where higher SEC22A mass-spec protein is associated with better disease-free survival. In most high-consensus cancer types, elevated SEC22A expression acts as an unfavorable survival marker, although some lineages such as HNSC show a favorable association.

HNSC, GBM, and PDAC are the cancer types where SEC22A mass-spec protein most reproducibly stratifies survival.

mass-spec protein survival associations by lineage

Ranked by sampling consensus. AUC1 and AUC2 indicate survival in the high- and low-expression groups, respectively; the lower AUC marks the poorer-surviving group. p-values are from the log-rank test.

Lineage	Measure	Split	Stage	AUC1 high	AUC2 low	p	Sampling consensus
HNSC	DFS	Median	All	0.778	0.505	<.001	68	view →
GBM	OS	Median	All	0.249	0.472	<.001	24	view →
PDAC	OS	Median	All	0.263	0.483	.014	12	view →
CCRCC	OS	Tertile	All	0.762	0.945	.004	11	view →
LUAD	DFS	Tertile	All	0.667	0.975	.025	4	view →

Pink = unfavorable, green = favorable. Showing the 5 strongest of 5 lineages.

SEC22A–HNSC (DFS)

Open the HNSC breakdown →